Exco InTouch, the leading provider of mobile patient communication solutions for the pharmaceutical and healthcare sectors, announces the new appointment of Director of Patient Recruitment, Judith Teall. The newly created position will drive Exco InTouch to build on its “patient centric” approach to managing clinical trials by identifying barriers to recruitment and retention, enhancing the crucial relationship between patient, trial processes and the sponsor company. Based at Exco InTouch’s European headquarters in Hertfordshire, UK, Teall’s role will see her lead and direct patient engagement solutions, lending her first-rate experience to further develop Exco’s recruitment, retention and compliance suite of services for the company’s biopharmaceutical sponsors and Contract Research Organization (CRO) clients.
Validating Exco InTouch’s growing stature in the eClinical arena, Teall joins the team with a distinguished patient recruitment background from Glaxo SmithKline, where she headed up patient recruitment across Europe, Asia Pacific, Africa and the Middle East. With over 20 years’ experience in the pharmaceutical clinical research area, Teall originally graduated from the Sheffield School of Nursing and spent her early career as a RGN nurse. Teall has an extensive understanding and insight into the healthcare arena through a variety of roles, firmly establishing herself as recruitment expert in the clinical research industry. Her work in guiding recruitment excellence, including developing enrolment strategies and delivering global monitoring training methods strengthens Exco’s global focus on patient recruitment and retention.
“Exco InTouch has been built on a very strong base of experienced personnel coupled with the innovative use of technology and service excellence, and is already well placed in the patient recruitment, retention and compliance arena. This was a key driver in my decision to join the company,” says Teall. “Exco’s industry expertise and commitment to a patient centric approach to developing all its services, made it an ideal match for my expertise in patient recruitment. I am looking forward to further enhancing the standards of global patient recruitment through effective enrolment and engagement strategies.”
Tim Davis, CEO, Exco InTouch, comments: “We believe in putting the patient experience at the heart of everything we do at Exco. Welcoming someone of Judith’s capabilities to our team further enhances our ability to develop these recruitment and engagement strategies and we see Judith as a vital addition to our efforts on this front. With her extensive experience in the industry, we believe Judith will be a key member of the team. Exco has grown significantly by innovative but pragmatic service development especially in the patient recruitment process and with this new appointment we plan to maximise the opportunity for recruitment, communication and engagement with all patient populations.”
Exco InTouch is the leading provider of regulatory compliant mobile technologies for recruitment, retention, compliance, engagement and data capture to the pharmaceutical and healthcare industries.
For further information on the Exco InTouch range of solutions, please call +44 1279 408 210 or +1 949 725 2946
About Exco InTouch
Exco InTouch (excointouch.com) is the leading provider of interactive patient communication solutions using internet and cell phone technology. Using a combination of software and services, Exco InTouch offers BioPharma sponsors, CROs and patient recruitment agencies the opportunity to improve patient recruitment, retention and compliance using timely notifications, alerts and two-way messages.
Additionally, Exco collects electronic patient reported outcomes (ePRO) and diary data using standard cell phone technology which is both cost effective for sponsors and extremely easy and convenient for trial subjects. These solutions are currently being used by hundreds of thousands of patients in over 70 countries, delivered in the local language and are fully compliant with HIPAA regulations, FDA CFR 21 Part 11 and all electronic communication privacy directives.